Literature DB >> 30239261

Influenza vaccination and the 'diversity paradox'.

Craig P Thompson1, Uri Obolski1.   

Abstract

The antigenic evolution of influenza is widely assumed to occur by antigenic drift, in which strains incrementally acquire mutations in highly variable epitopes under strong immune selective pressure, such as those in the major influenza antigen haemagglutinin. However, this is not easy to reconcile with epidemiological observations, which show that each influenza season is dominated by a limited number of strains. Here, we discuss this paradox in light of recent influenza epidemics that have been characterised by low vaccine effectiveness and dominated by strains of limited antigenic and genetic diversity.

Keywords:  Influenza; antigenic drift; antigenic evolution; antigenic thrift; seasonal vaccine; universal vaccine; vaccination; vaccine

Year:  2018        PMID: 30239261      PMCID: PMC6343615          DOI: 10.1080/21645515.2018.1504596

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  46 in total

1.  Ecological and immunological determinants of influenza evolution.

Authors:  Neil M Ferguson; Alison P Galvani; Robin M Bush
Journal:  Nature       Date:  2003-03-27       Impact factor: 49.962

2.  A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen.

Authors:  Antonietta Impagliazzo; Fin Milder; Harmjan Kuipers; Michelle V Wagner; Xueyong Zhu; Ryan M B Hoffman; Ruud van Meersbergen; Jeroen Huizingh; Patrick Wanningen; Johan Verspuij; Martijn de Man; Zhaoqing Ding; Adrian Apetri; Başak Kükrer; Eveline Sneekes-Vriese; Danuta Tomkiewicz; Nick S Laursen; Peter S Lee; Anna Zakrzewska; Liesbeth Dekking; Jeroen Tolboom; Lisanne Tettero; Sander van Meerten; Wenli Yu; Wouter Koudstaal; Jaap Goudsmit; Andrew B Ward; Wim Meijberg; Ian A Wilson; Katarina Radošević
Journal:  Science       Date:  2015-08-24       Impact factor: 47.728

3.  Chaos, persistence, and evolution of strain structure in antigenically diverse infectious agents.

Authors:  S Gupta; N Ferguson; R Anderson
Journal:  Science       Date:  1998-05-08       Impact factor: 47.728

Review 4.  Immunogenicity and safety of inactivated quadrivalent influenza vaccine in adults: A systematic review and meta-analysis of randomised controlled trials.

Authors:  Aye M Moa; Abrar A Chughtai; David J Muscatello; Robin M Turner; C Raina MacIntyre
Journal:  Vaccine       Date:  2016-07-02       Impact factor: 3.641

5.  Influenza Vaccine Effectiveness Against 2009 Pandemic Influenza A(H1N1) Virus Differed by Vaccine Type During 2013-2014 in the United States.

Authors:  Manjusha Gaglani; Jessica Pruszynski; Kempapura Murthy; Lydia Clipper; Anne Robertson; Michael Reis; Jessie R Chung; Pedro A Piedra; Vasanthi Avadhanula; Mary Patricia Nowalk; Richard K Zimmerman; Michael L Jackson; Lisa A Jackson; Joshua G Petrie; Suzanne E Ohmit; Arnold S Monto; Huong Q McLean; Edward A Belongia; Alicia M Fry; Brendan Flannery
Journal:  J Infect Dis       Date:  2016-01-06       Impact factor: 7.759

6.  A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years.

Authors:  Richard D Antrobus; Patrick J Lillie; Tamara K Berthoud; Alexandra J Spencer; James E McLaren; Kristin Ladell; Teresa Lambe; Anita Milicic; David A Price; Adrian V S Hill; Sarah C Gilbert
Journal:  PLoS One       Date:  2012-10-31       Impact factor: 3.240

7.  Influenza pandemics of the 20th century.

Authors:  Edwin D Kilbourne
Journal:  Emerg Infect Dis       Date:  2006-01       Impact factor: 6.883

8.  THE ANTIBODY RESPONSE OF HUMAN SUBJECTS VACCINATED WITH THE VIRUS OF HUMAN INFLUENZA.

Authors:  T Francis; T P Magill
Journal:  J Exp Med       Date:  1937-01-31       Impact factor: 14.307

9.  How single mutations affect viral escape from broad and narrow antibodies to H1 influenza hemagglutinin.

Authors:  Michael B Doud; Juhye M Lee; Jesse D Bloom
Journal:  Nat Commun       Date:  2018-04-11       Impact factor: 14.919

10.  A naturally protective epitope of limited variability as an influenza vaccine target.

Authors:  Craig P Thompson; José Lourenço; Adam A Walters; Uri Obolski; Matthew Edmans; Duncan S Palmer; Kreepa Kooblall; George W Carnell; Daniel O'Connor; Thomas A Bowden; Oliver G Pybus; Andrew J Pollard; Nigel J Temperton; Teresa Lambe; Sarah C Gilbert; Sunetra Gupta
Journal:  Nat Commun       Date:  2018-09-21       Impact factor: 14.919

View more
  2 in total

1.  Increased frequency of travel in the presence of cross-immunity may act to decrease the chance of a global pandemic.

Authors:  R N Thompson; C P Thompson; O Pelerman; S Gupta; U Obolski
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2019-06-24       Impact factor: 6.237

Review 2.  An Antigenic Thrift-Based Approach to Influenza Vaccine Design.

Authors:  Jai S Bolton; Hannah Klim; Judith Wellens; Matthew Edmans; Uri Obolski; Craig P Thompson
Journal:  Vaccines (Basel)       Date:  2021-06-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.